Literature DB >> 32775353

Pancreatic Fat Infiltration Is Associated with a Higher Risk of Pancreatic Ductal Adenocarcinoma.

Vishal Desai1, Kevin Patel2, Ravi Sheth3, Usman Barlass1, Yuet-Ming Chan1, Joy Sclamberg3, Faraz Bishehsari1.   

Abstract

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has a poor survival rate, partly due to delayed diagnosis. Identifying high-risk individuals could lead to early detection and improve survival. A number of risk factors such as alcohol consumption and metabolic syndrome are associated with fatty infiltration of the pancreas. Experimental models show that a fatty pancreas promotes tissue inflammation and fibrosis, which could promote PDAC.
METHODS: We conducted a case-control study in a single-university tertiary hospital. Sixty-eight PDAC cases with recent non-contrast computed tomography (CT) and 235 controls were studied. The controls had no history of malignancy and underwent CT colonography for cancer screening in the same period. Pancreatic fat was estimated by calculating pancreatic (P) attenuation, corrected to splenic (S) attenuation, measured in three 1.0-cm2 regions of the pancreas. The P.S100 value calculated was used to estimate fatty infiltration of the pancreas (FIP), with a lower P.S100 representing a higher FIP.
RESULTS: The PDAC patients had a lower BMI and a higher rate of type 2 diabetes mellitus. The P.S100 was lower in cases than in controls (86.452 vs. 92.414, p = 4.016e-06), suggesting that FIP is higher with PDAC. The risk of developing PDAC steadily increased significantly for the quartiles with a higher FIP compared to the low FIP quartile. No correlation between BMI and FIP (r = -0.1031179; 95% confidence interval [CI] -0.22267106 to 0.01949092) was found. Adjusting for confounders (age, sex, BMI, and DM), the risk of developing PDAC according to the FIP was estimated to be 3.75 (95% CI 1.9234408-7.993337; p = 0.000171). FIP was stable before and after the diagnosis of PDAC in 9 cases with prior CT scans when no pancreatic tumor was identifiable.
CONCLUSION: Fatty pancreas is associated with an increased risk of pancreatic cancer. Once confirmed in larger-scale studies, these findings could help to identify at-risk individuals, particularly in high-risk groups such as chronic alcohol consumers.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Alcohol; Fatty pancreas; Metabolic syndrome; Pancreatic cancer

Year:  2020        PMID: 32775353      PMCID: PMC7383241          DOI: 10.1159/000507457

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


  48 in total

1.  Noninvasive in vivo quantitative assessment of fat content in human liver.

Authors:  C Ricci; R Longo; E Gioulis; M Bosco; P Pollesello; F Masutti; L S Crocè; S Paoletti; B de Bernard; C Tiribelli; L Dalla Palma
Journal:  J Hepatol       Date:  1997-07       Impact factor: 25.083

2.  A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice.

Authors:  Bincy Philip; Christina L Roland; Jaroslaw Daniluk; Yan Liu; Deyali Chatterjee; Sobeyda B Gomez; Baoan Ji; Haojie Huang; Huamin Wang; Jason B Fleming; Craig D Logsdon; Zobeida Cruz-Monserrate
Journal:  Gastroenterology       Date:  2013-08-16       Impact factor: 22.682

3.  Pancreatic fatty degeneration and fibrosis as predisposing factors for the development of pancreatic ductal adenocarcinoma.

Authors:  Yasuhiko Tomita; Kanako Azuma; Yuji Nonaka; Yoshihiro Kamada; Miki Tomoeda; Mioka Kishida; Masahiro Tanemura; Eiji Miyoshi
Journal:  Pancreas       Date:  2014-10       Impact factor: 3.327

Review 4.  Fat storage in pancreas and in insulin-sensitive tissues in pathogenesis of type 2 diabetes.

Authors:  F Assimacopoulos-Jeannet
Journal:  Int J Obes Relat Metab Disord       Date:  2004-12

5.  Enhancement of carcinogenesis and fatty infiltration in the pancreas in N-nitrosobis(2-oxopropyl)amine-treated hamsters by high-fat diet.

Authors:  Mika Hori; Tsukasa Kitahashi; Toshio Imai; Rikako Ishigamori; Shinji Takasu; Michihiro Mutoh; Takashi Sugimura; Keiji Wakabayashi; Mami Takahashi
Journal:  Pancreas       Date:  2011-11       Impact factor: 3.327

6.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

Review 7.  Pancreatic cancer.

Authors:  Audrey Vincent; Joseph Herman; Rich Schulick; Ralph H Hruban; Michael Goggins
Journal:  Lancet       Date:  2011-05-26       Impact factor: 79.321

8.  Adipose atrophy of the exocrine pancreas.

Authors:  M N Walters
Journal:  J Pathol Bacteriol       Date:  1966-10

9.  Quantitative assessment of pancreatic fat by using unenhanced CT: pathologic correlation and clinical implications.

Authors:  So Yeon Kim; Haeryoung Kim; Jai Young Cho; Soo Lim; Kyusun Cha; Kyoung Ho Lee; Young Hoon Kim; Ji Hoon Kim; Yoo-Seok Yoon; Ho-Seong Han; Heung Sik Kang
Journal:  Radiology       Date:  2014-01-16       Impact factor: 11.105

10.  Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma.

Authors:  Matthew H G Katz; Huamin Wang; Jason B Fleming; Charlotte C Sun; Rosa F Hwang; Robert A Wolff; Gauri Varadhachary; James L Abbruzzese; Christopher H Crane; Sunil Krishnan; Jean-Nicolas Vauthey; Eddie K Abdalla; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans
Journal:  Ann Surg Oncol       Date:  2009-02-05       Impact factor: 5.344

View more
  3 in total

Review 1.  Excess Body Weight and Pancreatic Disease.

Authors:  Mats L Wiese; Ali A Aghdassi; Markus M Lerch; Antje Steveling
Journal:  Visc Med       Date:  2021-07-09

Review 2.  Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, "Prediabetes," Diabetes and Atherosclerosis.

Authors:  T D Filippatos; K Alexakis; V Mavrikaki; D P Mikhailidis
Journal:  Dig Dis Sci       Date:  2021-01-19       Impact factor: 3.199

Review 3.  Uniting epidemiology and experimental models: pancreatic steatosis and pancreatic cancer.

Authors:  Emily Truong; Stephen Pandol; Christie Jeon
Journal:  EBioMedicine       Date:  2022-04-08       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.